All In MedTech

Device Trial Radar · NCT07823465

RNS System for Drug-Resistant Focal Epilepsy in Adolescents: A Real-World Study

A Real-World Evidence Study to Support Label Expansion for the NeuroPace RNS System for Drug-Resistant Focal Epilepsy in Adolescent Patients in the United States

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

Feb 2027

Study completion May 2027

Sponsor

Lead sponsor
NeuroPaceNot on our public-company list
Sponsor type
Industry
Collaborators
OM1, Inc.
First posted
Sep 16, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 13 years, up to 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The NeuroPace RNS System is FDA-approved for adults with drug-resistant focal epilepsy but is not yet approved for adolescents. This study uses real-world data to evaluate the RNS System's safety and effectiveness in adolescents aged 12 through 17 who have already received the device in routine clinical practice. Data will come from patient-authorized electronic health records and patient-reported outcomes collected through a central study site, not a traditional trial infrastructure. Up to 100 evaluable patients across the United States sites will be enrolled, with results intended to support expansion of the RNS System's approved indication to include this adolescent population.

Conditions

  • Focal Epilepsy
  • Drug-resistant Focal Epilepsy

Interventions

  • NeuroPace RNS SystemDevice

    The NeuroPace RNS System is an implantable, closed-loop responsive neurostimulation device for drug-resistant focal epilepsy. It continuously monitors electrocorticographic activity through leads placed at one or two seizure foci in the brain and, when it detects the electrical patterns associated with seizure onset, delivers brief, typically imperceptible electrical stimulation directly to that focus to interrupt the seizure before it spreads or produces symptoms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Serious Adverse Device Events (SADE)Time frame: Implantation through 84 days post-implant
  2. Responder Rate (RR50) at 24 monthsTime frame: 24 months post-implant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OM1's Central Site (Virtual Site)

    Waltham, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.